Entered Material Transfer Agreement (MTA)
with University
of Queensland
in January 2021

​

Exclusive rights for AEZS to negotiate a license agreement for the commercial use of the results

​

University researchers to secure grants and conduct preclinical and clinical studies

 

AEZS as co-investigator providing medication as well as preclinical and clinical know-how

Investigation as a potential
treatment for Amyotrophic Lateral Sclerosis (ALS,
Lou Gehrig's disease)

 

Neurodegenerative

motor neuron disease (MND)

with significant unmet medical need